| Index | S&P 500 | P/E | 10.43 | EPS (ttm) | 8.19 | Insider Own | - | Shs Outstand | 170.22M | Perf Week | -0.47% |
| Market Cap | 14.54B | Forward P/E | 11.64 | EPS next Y | 7.33 | Insider Trans | 0.00% | Shs Float | 144.14M | Perf Month | -3.59% |
| Enterprise Value | 19.42B | PEG | 0.88 | EPS next Q | - | Inst Own | - | Short Float | 3.40% | Perf Quarter | 6.14% |
| Income | 1.43B | P/S | 1.75 | EPS this Y | 18.65% | Inst Trans | - | Short Ratio | 4.71 | Perf Half Y | 24.65% |
| Sales | 8.31B | P/B | 3.03 | EPS next Y | 2.50% | ROA | 10.07% | Short Interest | 4.89M | Perf YTD | 7.79% |
| Book/sh | 28.20 | P/C | 36.08 | EPS next 5Y | 11.80% | ROE | 28.96% | 52W High | 94.16 -9.29% | Perf Year | 17.39% |
| Cash/sh | 2.37 | P/FCF | - | EPS past 3/5Y | 4.46% 6.11% | ROIC | 15.85% | 52W Low | 62.38 36.92% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 7.87 | Sales past 3/5Y | 0.79% 2.72% | Gross Margin | 54.69% | Volatility | 1.89% 2.23% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 2.34 | EPS Y/Y TTM | 196.74% | Oper. Margin | 24.99% | ATR (14) | 2.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.74 | Sales Y/Y TTM | 0.68% | Profit Margin | 17.26% | RSI (14) | 42.92 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.02 | EPS Q/Q | 50.89% | SMA20 | -1.87% | Beta | 0.56 | Target Price | 91.13 |
| Payout | 0.00% | Debt/Eq | 1.00 | Sales Q/Q | 2.22% | SMA50 | -3.57% | Rel Volume | 1.54 | Prev Close | 87.45 |
| Employees | 20,584 | LT Debt/Eq | 1.00 | Earnings | Nov 05 | SMA200 | 8.97% | Avg Volume | 1.07M | Price | 85.41 |
| IPO Date | Apr 01, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 33.89% 2.55% | Net Debt/EBITDA | 1.98 | Volume | 1,644,106 | Change | -2.33% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-06-26 | Reiterated | Stifel Nicolaus | $90 → $100 | |
| Aug-06-26 | Reiterated | Mizuho Securities | Outperform | $100 → $113 |
| Aug-06-26 | Reiterated | Keybanc | Overweight | $93 → $102 |
| Aug-06-26 | Reiterated | BTIG | Buy | $91 → $95 |
| Aug-06-26 | Reiterated | UBS | Buy | $95 → $101 |
| Jul-28-26 | Upgrade | UBS | Neutral → Buy | $78 → $95 |
| Jul-13-26 | Reiterated | BTIG | Buy | $89 → $91 |
| Jul-08-26 | Reiterated | BMO Capital | $81 | |
| Jun-01-26 | Reiterated | Jefferies | $43 | |
| May-15-26 | Initiated | Wedbush | Outperform | $94 |
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 8,310 | 8,325 | 8,254 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 3,765 | 3,874 | 3,661 | — | — | — | — | |
| Gross Profit | 4,545 | 4,451 | 4,593 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 3,293 | 3,080 | 2,782 | — | — | — | — | |
| Research and Development | 726 | 739 | 775 | — | — | — | — | |
| Other Operating Expense | -1,551 | -1,549 | 0 | — | — | — | — | |
| Operating Income | 2,077 | 2,181 | 1,036 | — | — | — | — | |
| Interest Expense | 266 | 347 | 367 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -115 | -121 | -64 | — | — | — | — | |
| Net Income Before Taxes | 1,696 | 1,713 | 605 | — | — | — | — | |
| Income Taxes | 261 | 157 | 127 | — | — | — | — | |
| Consolidated Net Income | 1,434 | 1,556 | 479 | — | — | — | — | |
| Net Income From Continuing Operations | 1,435 | 1,556 | 478 | — | — | — | — | |
| Net Income | 1,434 | 1,556 | 479 | — | — | — | — | |
| EPS (Recurring) | 8.22 | 8.94 | 2.77 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 8.22 | 8.94 | 2.77 | — | — | — | — | |
| EPS (Diluted) | 8.19 | 8.88 | 2.76 | — | — | — | — | |
| EBITDA | 2,468 | 2,549 | 1,527 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 10.43 | 8.92 | 23.93 | — | — | — | — | |
| Price To Sales Ratio | 1.79 | 1.66 | 1.38 | — | — | — | — | |
| Gross Margin | 54.69 | 53.47 | 55.65 | — | — | — | — | |
| Operating Margin | 24.99 | 26.20 | 12.55 | — | — | — | — | |
| Net Margin | 17.26 | 18.69 | 5.80 | — | — | — | — | |
| Shares Outstanding | 174 | 174 | 173 | — | — | — | — | |
| Market Capitalization | 14,861 | 13,788 | 11,428 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hanson Bryan C | Chief Executive Officer | Sep 01 '26 | Option Exercise | 0.00 | 67,261 | 0 | 211,983 | Sep 03 |
| Wilcox Mary T | Chief Accounting Officer | May 13 '26 | Option Exercise | 0.00 | 2,376 | 0 | 7,632 | May 15 |
| Gomez Tammy L | Chief Human Resources Officer | May 13 '26 | Option Exercise | 0.00 | 3,960 | 0 | 15,030 | May 15 |
| McMillan Wayde D. | Chief Financial Officer | May 13 '26 | Option Exercise | 0.00 | 9,503 | 0 | 53,041 | May 15 |
| Harrington Paul S | Chief Supply Chain Officer | May 13 '26 | Option Exercise | 0.00 | 3,960 | 0 | 22,130 | May 15 |
| Kirberger Marcela A. | Chief Legal Affairs Officer | May 13 '26 | Option Exercise | 0.00 | 4,488 | 0 | 15,492 | May 15 |
| Hanson Bryan C | Chief Executive Officer | May 13 '26 | Option Exercise | 0.00 | 34,315 | 0 | 158,225 | May 15 |
| Landucci Amy | Chief Information Officer | May 13 '26 | Option Exercise | 0.00 | 4,422 | 0 | 41,905 | May 15 |
| Wendell Amy McBride | Director | Apr 30 '26 | Option Exercise | 0.00 | 3,403 | 0 | 10,422 | May 01 |
| WEILAND JOHN H | Director | Apr 30 '26 | Option Exercise | 0.00 | 3,403 | 0 | 8,947 | May 01 |
| Mily Elizabeth | Director | Apr 30 '26 | Option Exercise | 0.00 | 3,403 | 0 | 9,009 | May 01 |
| Wilson Darryl L. | Director | Apr 30 '26 | Option Exercise | 0.00 | 3,403 | 0 | 8,947 | May 01 |
| MAY KAREN J | Director | Apr 30 '26 | Option Exercise | 0.00 | 3,403 | 0 | 8,947 | May 01 |
| Harris Bernard A Jr | Director | Apr 30 '26 | Option Exercise | 0.00 | 3,403 | 0 | 8,947 | May 01 |
| EISENBERG GLENN A | Director | Apr 30 '26 | Option Exercise | 0.00 | 3,403 | 0 | 8,947 | May 01 |